JGJeffery Goad

Jeffery Goad

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jeffery Goad has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical consultation: The role of vitamin A in the management of confirmed acute measles infection

    by Michael Raschka, Dustin Le, Patricia Stinchfield, Summer Davies, Jeffery Goad

    Purpose: Although measles was declared eliminated in the United States in 2000, the rate of measles infection in 2026 is the highest in more than 3 decades. This clinical consultation explores the role of vitamin A in the treatment of acute measles infection and the challenges posed with this treatment in pediatric patients due to the limitations in currently available formulations. Summary: The role of vitamin A in the treatment of acute, confirmed measles infection has been well established and is recommended by major medical organizations, including the World Health Organization and American Academy of Pediatrics. Despite the benefits that vitamin A has demonstrated in past studies, treatment with vitamin A remains difficult due to challenges in administration secondary to the limited formulations currently available in the United States. Multiple options exist to extract liquid vitamin A from capsules, but these methods are cumbersome and possess significant challenges. Conclusion: Vitamin A treatment should be used in patients with acute, confirmed measles infection, after confirming that they are not at risk for drug interactions and have no symptoms of vitamin A toxicity if they were previously treated with vitamin A. A concentrated liquid formulation of vitamin A approved by the US Food and Drug Administration is needed to overcome current obstacles with administration of vitamin A in pediatric patients unable to swallow capsules.

  • Immunoglobulin Use, Availability, and Administration Considerations in Measles Prevention

    by Dustin Le, Amina Ahmed, Michael Raschka, Patricia Stinchfield, Jeffery Goad

    In 2026, the National Foundation for Infectious Diseases (NFID), with the Infectious Diseases Society of America (IDSA), convened a Measles Summit in response to the largest U.S. measles resurgence in over three decades, with more than 3,000 confirmed cases mostly among unvaccinated individuals. Many clinicians and public health professionals have limited firsthand measles experience, underscoring the need for clinical guidance. In this commentary, we examine immune globulin (IG) use for measles post-exposure prophylaxis (PEP) amid fragile supply and logistical challenges. GamaSTAN®, the sole Food and Drug Administration (FDA)-licensed intramuscular IG product, faces episodic availability, non-returnable single-vial economics, and a 2013 recommendation to double the PEP dose, increasing per-patient demand. IVIG is increasingly employed when patients weigh 30 kg or more, beyond the weight at which an adequate dose of immune globulin can be given intramuscularly, or when IMIG supply is constrained, while concurrent lot withdrawals compromise institutional formularies. We review evidence-based patient selection for PEP, emphasizing that the Measles, Mumps, and Rubella (MMR) vaccine remains first-line within 72 hours of exposure, with IG reserved when vaccination is contraindicated or potentially ineffective. Immunosuppressive therapies vary widely in their effects on the safety and efficacy of live vaccines. We therefore argue against categorizing every biologic, immunomodulator, or steroid as an automatic MMR contraindication, which would overestimate IG-PEP demand and preclude MMR for eligible patients. We propose class-specific stratification and an electronic health record decision-support rule to better align IG demand with genuine need. Finally, we address declining potency standards for measles antibody, attributable to waning donor titers, and offer guidance on dosing, multi-site pediatric administration, and infusion logistics within the PEP window.

  • Open Access

    Expert Recommendations to Strengthen Chikungunya Outbreak Surveillance and Reporting for Traveler Health Protection

    by Daniel C. Payne, Karoun H. Bagamian, Jeffery Goad, Nathan D. Grubaugh, Michael A. Johansson, Moritz U. G. Kraemer, Eyal Leshem, Francesca F. Norman, Alfonso J. Rodríguez-Morales, Henrik Salje, et al.

    : Chikungunya, a debilitating mosquito-borne disease caused by chikungunya virus, has surged dramatically in the past two decades. Chikungunya outbreaks can intensify rapidly, with infections posing a significant endemic health burden in tropical/subtropical areas and for travelers. Health professionals require timely and accurate outbreak information to adequately protect travelers and assess chikungunya risk. However, detection is often insufficient in the areas most susceptible to outbreaks, leading to diagnostic and reporting delays. Consequently, travelers are often unaware of increased chikungunya infection risk at their destination. We assessed chikungunya surveillance and reporting resources, and we developed expert recommendations for traveler health protection. Because data-reporting cadences, reliability, and availability vary, we organized structured activities and convened an expert panel to compare these resources and evaluate their strengths and weaknesses. We provide a synthesis of the expert panel discussion and provide recommendations on how to improve chikungunya surveillance and risk communication to travelers. Assessing outbreak risk requires using multiple local and international reporting resources because no single resource contains all of the necessary information. The panelists identified several challenges regarding chikungunya surveillance and outbreak reporting: inadequate chikungunya surveillance infrastructure and diagnostic capacity; varying case definitions; limited understanding of the local health care context; inadequate awareness of chikungunya in health care settings; and restricted or delayed access to real-time surveillance data. As chikungunya risk increases worldwide, greater attention and resources are needed to improve timely, sensitive, and specific diagnostic testing and rapid communication to health care workers and travelers, particularly in resource-poor regions where outbreaks occur.


  • Open Access

    Ready for takeoff? exploring United States health care providers’ pretravel consultation priorities, gaps, barriers, and opportunities

    by Katherine A. Reifler, Swati S. Sharma, Nicholas A. Bergren, Elizabeth D. Barnett, Lin H. Chen, Jeffery A. Goad, William B. Macleod, Laura Kogelman, Davidson H. Hamer


  • Open Access

    Using Community Pharmacy Immunization Screening Forms to Identify Potential Immunization Opportunities

    by Albert T. Bach, Jeffery A. Goad

    Immunization screening forms are completed for each patient that is to be vaccinated in the pharmacy. Screening forms contain demographic and health questions, which are used to determine if a patient is contraindicated to receive a vaccine. The objective is to determine if patient responses to questions on these forms can be used to identify potential vaccine indications. De-identified data was retrospectively collected from 11 community pharmacies in California and Michigan that included basic demographics, answers to immunization screening questions, and vaccine(s) administered during that visit. The Advisory Committee on Immunization Practices (ACIP) recommendations were used to forecast vaccine needs using the limited demographic and health history available from the screening forms. Descriptive statistics are presented, characterizing patient demographics and health condition-based recommendations, and the percentage of patients in a pharmacy population that may have potential indications for additional vaccines. Data were collected from 8669 pharmacy vaccine screening forms. Using the patient’s date of birth on the screening form, 10% (n = 759) and 34.6% (n = 2615) of patients receiving vaccines at the pharmacy may be indicated for the zoster, or both the zoster and pneumococcal vaccines, respectively. Screening form questions that inquire about medical history are also able to identify 13.9% (n = 977) of patients with a potential need for pneumococcal vaccines. Our data indicate that pharmacists can identify potential immunization opportunities proactively by using their immunization screening form, not only to identify contraindications, but also indications.


  • Open Access

    Pharmacy-Based Travel Health Services in the United States

    by Keri Hurley-Kim, Jeffery Goad, Sheila Seed, Karl M. Hess

    The aim of this paper is to review pharmacy laws and regulations, pharmacist training, clinic considerations, and patient care outcomes regarding pharmacy-based travel health services in the United States. Pharmacists and pharmacies in the United States are highly visible and accessible to the public, and have long been regarded as a source for immunization services. As international travel continues to increase and grow in popularity in this country, there is a pressing need for expanded access to preventative health services, including routine and travel vaccinations, as well as medications for prophylaxis or self-treatment of conditions that may be acquired overseas. In the United States, the scope of pharmacy practice continues to expand and incorporate these preventable health services to varying degrees on a state-by-state level. A literature review was undertaken to identify published articles on pharmacist- or pharmacy-based travel health services or care in the United States. The results of this paper show that pharmacists can help to increase access to and awareness of the need for these services to ensure that patients remain healthy while traveling abroad, and that they do not acquire a travel-related disease while on their trip. For those pharmacists interested in starting a travel health service, considerations should be made to ensure that they have the necessary training, education, and skill set in order to provide this specialty level of care, and that their practice setting is optimally designed to facilitate the service. While there is little published work available on pharmacy or pharmacist-provided travel health services in the United States, outcomes from published studies are positive, which further supports the role of the pharmacist in this setting.


  • Open Access

    Pharmacy-Based Travel Health Services in the United States

    by Keri Hurley-Kim, Jeffery Goad, Sheila Seed, Karl Hess

    Pharmacists and pharmacies are highly visible and accessible to the public and have long been regarded as a source for immunization services in the United States. As international travel continues to increase and grow in popularity in this country, there is a pressing need for expanded access to preventative health services including routine and travel vaccinations and medications for prophylaxis or self-treatment of conditions that may be acquired overseas. In the United States, the scope of pharmacy practice continues to expand and incorporate these preventable health services to varying degrees on a state-by-state level. As a result, pharmacists can help to increase access to and awareness of the need for these services to insure that patients remain healthy while traveling abroad and that they do not acquire a travel-related disease while on their trip. For those pharmacists interested in starting a travel health service, considerations should be undertaken that ensures that they have the necessary training, education, and skill set in order to provide this specialty level of care and that their practice setting is optimally designed to facilitate this service. Outcomes from studies that have evaluated pharmacy-based travel health services are positive, which further supports the role of the pharmacist in this setting. Therefore, the purpose of this paper is to highlight United States pharmacy laws and regulations, pharmacist training, travel clinic considerations, and patient care outcomes from pharmacy-based travel health services.


  • Knowledge, attitudes, and practices regarding influenza vaccination among health professional students

    by Joycelyn Mallari, Jeffery Goad, W.U. Joanne, Kathleen Johnson, Todd Forman, Lawrence Neinstein